



INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

ATTY. DOCKET NO.  
11221/5

SERIAL NO.  
09/691,504

APPLICANT  
Wallack et al.

FILING DATE  
October 18, 2000

GROUP  
1646

RECEIVE

JUL 25 2001

TECH CENTER 1600/29

1646

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
A	4,108,983	August 22, 1978	Wallack	424	89	
	4,863,727	September 5, 1989	Zimmerman et al.	424	85.2	
	5,030,621	July 9, 1991	Bystryn	514	21	
	5,066,489	November 19, 1991	Paradise et al.	424	85.2	
	5,290,551	March 1, 1994	Berd	424	88	
	5,425,940	June 20, 1995	Zimmerman et al.	424	85.1	
	5,478,556	December 26, 1995	Elliott et al.	424	85.2	
	5,484,596	January 16, 1996	Hanna, Jr. et al.	424	277.1	
	5,635,188	June 3, 1997	Bystryn	424	277.1	
	5,788,963	August 4, 1998	Murphy et al.	424	93.21	

\* - If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	DATE CONSIDERED
A	12/12/07
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>ATTY. DOCKET NO.</b> 11221/5	<b>SERIAL NO.</b> 09/691,504
	<b>APPLICANT</b> Wallack et al.	
	<b>FILING DATE</b> October 18, 2000	<b>GROUP</b> 1646


 OCT 03 2001  
 TECH CENTER 1600/2900

## U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

\* - If pertinent

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
AW		Tueting T. et al., "Autologous Human Monocyte-derived Dendritic Cell Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses in Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-biasing Cytokines IL-12 and IFN- $\alpha$ 1", J. Immunol. Vol. 160, 1998, pp. 1139-1147.
		Quin H. et al., "Recombinant Vaccinia Expressing Interleukin-2 for Cancer Gene Therapy", Cancer Gene Therapy, Vol. 3, No. 3, 1996, pp. 163-167.
		Abde-Wahab Z. et al., "Human Dendritic Cells, Pulsed with Either Melanoma Tumor Cell Lysates or the Gp100 Peptide (280-288), Induce Pairs of T-cell Cultures with Similar Phenotype and Lytic Activity", Cellular Immunology, Vol. 186, No. 1, May 25, 1998 (pp. 63-74).
		Sivanandham M. et al., "Prospects for Gene Therapy and Lymphokine Therapy for Metastatic Malanoma", Ann. Plastic Surg., Vol. 28, No. 1, 1992, pp. 114-118.
		Mukherji B and Chakraborty NG., "Immunobiology and immunotherapy of melanoma," Curr.Opin.Oncol.7:175-184, 1995.
		Wallack MK, Sivanandham M, Balch CM, et al., "Favorable Clinical Responses In Subsets of Patients From A Randomized, Multi-Institutional Melanoma Vaccine Trial," Ann.Surg.Oncol.3(2):1-8, 1996.
		Lotze MT et al., "High dose recombinant interleukin-2 in the treatment of patients with disseminated cancers," JAMA 256(22):3117-3124, 1986.
		West WH et al., "Constant infusion of recombinant IL-2 in adoptive immunotherapy of advanced cancers," New Engl.J.Med. 316(15):898-905, 1987.

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
AW		Qin H, Catterjee SK, "Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF," Hum. Gene Ther. 7(15):1853-60, Oct. 1, 1996.
		Shrayer DP, Bogaars H, Hearing VJ, Wanebo HJ, "Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy," J.Exp.Ther.Oncol., 1(2):126-33, 1996.
		Rosenberg et al., "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma," New Engl.J.Med.319:1676-1680, 1988.
		Dutcher et al., "A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma," J.Clin.Oncol. 9(4):641-648, 1991.
		Siegel et al., "Interleukin-2 toxicity," J.Clin.Oncology, 9:694-704, 1991.
		Pardoll DM, "Cancer vaccines," Nat.Med. 4(5 Suppl): 525-31, 1998.
		Nestle FO et al., "Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells," Nat.Med.4(3):328-332, 1998.
		Hsu et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," Nat.Med. 2(1):52-58, 1996.
		Villikka K et al, "Cytokine therapy of malignant melanoma," Ann.Med.28(3):227-233, 1996.
		Kirkin AF et al., "Generation of human-melanoma-specific T lymphocyte, clones defining novel cytolytic targets with panels of newly established melanoma cell lines," Cancer Immunol. Immunother.41(2):71-81, 1995.
		Celluzzi CM et al., "Cutting Edge: Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection," J.Immunol.160(7):3081-3085, 1998.
		Flexner C et al., "Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression," Nature 330:259-262, 1987.
		Sivanandham M et al., "Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model," Cancer Immunol. Immunother.38:259-264, 1994.
		Lee SS et al., "Vaccinia virus vector mediated cytokine gene transfer for in vivo tumor immunotherapy, Proc.Am.Assoc.Can.Res.1035:514, 1994.
		Miyahira Y et al., "Quantification of antigen specific CD8+ T cells using an ELISPOT assay", J. Immunol.Meth.181:45-54, 1995.

RECEIVED

OCT 03 2001

TECH CENTER 1600/2

EXAMINER <i>Allee</i>	DATE CONSIDERED <i>12/12/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	